Non-Hodgkin's Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Non-Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-Hodgkin's Lymphoma Pipeline Outlook
Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report
In March 2025, Hoffmann-La Roche conducted a phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma.
In March 2025, Bristol-Myers Squibb organized a phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working to develop 220+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
The leading Non-Hodgkin Lymphoma Companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.
Stay ahead with the most recent pipeline outlook for Non-Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Hodgkin's Lymphoma Treatment Drugs
Non-Hodgkin Lymphoma Emerging Drugs Profile
Mosunetuzumab: Hoffmann-la Roche
Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. Mosunetuzumab is equipped with structural features that promote T-cell recruitment and retention, resulting in an antitumor effect. In preclinical models, mosunetuzumab induced T-cell proliferation and B-cell death; furthermore, efficient B-cell killing was achieved at low effector-to-target (T cell:B cell) ratios. Use of mosunetuzumab in combination with PD-L1 inhibition may address adaptive immune resistance mechanisms to enhance anticancer activity against B-cell malignancies. The drug is being evaluated in Phase III Study to evaluate the efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive b-cell Non-Hodgkin's Lymphoma.
Tisagenlecleucel: Novartis
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient's T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR is comprised of a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains from 4-1BB (CD137) and CD3 zeta Label. These intracellular costimulatory signaling domains increase the expansion, longer-term persistence and potency of CAR T cells: the CD3 zeta component is critical for initiating T-cell activation and antitumor activity, while 4-1BB enhances the expansion and persistence of tisagenlecleucel {FDA Label, A20379]. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.
Capivasertib: AstraZeneca
Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.
BI-1206: BioInvent
BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin's lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients.
HMPL-760: Hutchmed
HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.
The Non-Hodgkin's Lymphoma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin's Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin's Lymphoma Treatment.
Non-Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin's Lymphoma market
Explore groundbreaking therapies and clinical trials in the Non-Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Non-Hodgkin's Lymphoma Drugs
Non-Hodgkin's Lymphoma Companies
Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences Inc. and others.
Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical
Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Unveil the future of Non-Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-Hodgkin's Lymphoma Market Drivers and Barriers
Scope of the Non-Hodgkin Lymphoma Pipeline Report
Coverage- Global
Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.
Get the latest on Non-Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-Hodgkin's Lymphoma Companies, Key Products and Unmet Needs
Table of Content
Introduction
Non-Hodgkin's Lymphoma Executive Summary
Non-Hodgkin Lymphoma: Overview
Non-Hodgkin's Lymphoma Pipeline Therapeutics
Non-Hodgkin's Lymphoma Therapeutic Assessment
Non-Hodgkin Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Tisagenlecleucel: Novartis
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Capivasertib: AstraZeneca
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
BI-1206: BioInvent
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
HMPL-760: Hutchmed
Drug profiles in the detailed report…..
Preclinical Stage Products
Product Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Non-Hodgkin Lymphoma Key Companies
Non-Hodgkin Lymphoma Key Products
Non-Hodgkin Lymphoma- Unmet Needs
Non-Hodgkin Lymphoma- Market Drivers and Barriers
Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
Non-Hodgkin Lymphoma Analyst Views
Non-Hodgkin Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 hours ago
- Cision Canada
Alithya reports year over year continued improvement Français
Q1-2026 Highlights Revenues increased 2.7% to $124.2 million, compared to $120.9 million for the same quarter last year. 84.8% of revenues were generated from clients which we had in the same quarter last year. Gross margin increased 3.3% to $39.8 million, compared to $38.5 million for the same quarter last year. Gross Margin as a Percentage of Revenues (a) increased to 32.1%, compared to 31.9% for the same quarter last year. Selling, general and administrative expenses decreased by $1.1 million, or 3.4%, to $30.6 million, compared to $31.7 million for the same quarter last year. Selling, general and administrative expenses as a percentage of revenues (a) decreased to 24.6%, from 26.2% for the same quarter last year. Net earnings increased to $0.2 million, or nil per share, compared to a net loss of $2.8 million, or $0.03 per share, for the same quarter last year. Adjusted Net Earnings (b) increased by $1.6 million, or 31.8%, to $6.5 million, from $4.9 million for the same quarter last year. This translated into Adjusted Net Earnings per Share (b) of $0.07, compared to $0.05 for the same quarter last year. Adjusted EBITDA (b) increased by $1.5 million, or 15.6%, to $11.6 million, for an Adjusted EBITDA Margin (b) of 9.4% of revenues, compared to $10.1 million, for an Adjusted EBITDA Margin (b) of 8.3% of revenues, for the same quarter last year. Net cash used in operating activities was $4.2 million, representing a decrease of $20.9 million, from $16.7 million of cash generated for the same quarter last year. Q1 Bookings (a) reached $118.1 million, which translated into a Book-to-Bill Ratio (a) of 0.95 for the quarter. The Book-to-Bill Ratio would have been 1.06 if revenues from the two long-term contracts signed as part of an acquisition in the first quarter of fiscal year 2022 were excluded. Backlog (a) represented approximately 15 months of trailing twelve-month revenues as at June 30, 2025. Signed 20 new clients. Acquired eVerge Interests, Inc. and its subsidiaries (the "eVerge Acquisition", "eVerge"), on May 31, 2025, specializing in enterprise application and transformation services. Subsequent to June 30, 2025, Pierre Blanchette joined Alithya as Chief Financial Officer and the Company extended the maturity of the subordinated unsecured loans to October 2027. MONTREAL, Aug. 13, 2025 /CNW/ - Alithya Group inc. (TSX: ALYA) ("Alithya" or the "Company") reported today its results for the first quarter of fiscal 2026 ended June 30, 2025. All amounts are in Canadian dollars unless otherwise stated. Summary of the financial results for the first quarter: (a) These are other financial measures without a standardized definition under IFRS, which may not be comparable to similar measures used by other issuers. See "Non-IFRS and Other Financial Measures" below. (b) These are non-IFRS financial measures without a standardized definition under IFRS, which may not be comparable to similar measures used by other issuers. More information and quantitative reconciliations of Adjusted Net Earnings and Adjusted EBITDA to the most directly comparable IFRS measures are presented below under the caption "Non-IFRS and Other Financial Measures". "Adjusted EBITDA Margin" refers to the percentage of total revenue that Adjusted EBITDA represents for a given period. Quote by Paul Raymond, President and CEO, Alithya: "The Alithya team has delivered another quarter of year over year improvements in many areas of the business. We achieved double digit organic growth in our US operations, as clients seek to roll out the latest mission critical cloud enterprise systems to better leverage data and AI capabilities. This is a clear indication of our position as a trusted advisor. We have also harnessed synergies from our latest acquisitions to bolster our client offerings, enabling us to better support our clients. Our team remains focused on executing our long-term plan of profitable growth and value creation." First Quarter Results Revenues Revenues amounted to $124.2 million for the three months ended June 30, 2025, representing an increase of $3.3 million, or 2.7%, from $120.9 million for the three months ended June 30, 2024. Revenues in Canada decreased by $5.5 million, or 8.5%, to $59.6 million for the three months ended June 30, 2025, from $65.1 million for the three months ended June 30, 2024. The decrease in revenues was due primarily to reduced revenues from government contracts, certain client projects reaching maturity, and one less billable day compared to the same quarter last year, partially offset by revenues from the acquisition of XRM Vision Inc. and its subsidiaries on December 1, 2024 (the "XRM Acquisition", "XRM Vision"), and a continued recovery in the banking sector. U.S. revenues increased by $8.8 million, or 17.3%, to $59.5 million for the three months ended June 30, 2025, from $50.7 million for the three months ended June 30, 2024, due primarily to organic growth in enterprise transformation services, higher billing rates, revenues from eVerge since its acquisition, and a favorable US$ exchange rate impact of $0.7 million between the two periods. International revenues increased by $0.1 million, or 0.7%, to $5.1 million for the three months ended June 30, 2025, from $5.0 million for the three months ended June 30, 2024. Gross Margin Gross margin increased by $1.3 million, or 3.3%, to $39.8 million for the three months ended June 30, 2025, from $38.5 million for the three months ended June 30, 2024. Gross margin as a percentage of revenues increased to 32.1% for the three months ended June 30, 2025, from 31.9% for the three months ended June 30, 2024. In Canada, gross margin as a percentage of revenues decreased compared to the same quarter last year, mainly due to decreases in utilization rates and tax credits, and salary increases that came into effect at the beginning of this fiscal year, partially offset by a positive margin contribution from XRM Vision since its acquisition. In the U.S., gross margin as a percentage of revenues increased compared to the same quarter last year, primarily due to increased efficiencies, higher billing rates, and the increased use of our smart shoring capabilities. International gross margin as a percentage of revenues decreased compared to the same quarter last year, mainly due to lower utilization. Selling, General and Administrative Expenses Selling, general and administrative expenses totaled $30.6 million for the three months ended June 30, 2025, representing a decrease of $1.1 million, or 3.4%, from $31.7 million for the three months ended June 30, 2024, despite the addition of expenses from XRM Vision and eVerge since their acquisitions. Selling, general and administrative expenses as a percentage of revenues amounted to 24.6% for the three months ended June 30, 2025, compared to 26.2% for the same period last year. The decrease in selling, general and administrative expenses was mainly due to decreased employee compensation costs, stemming from variable compensation and $1.5 million in severance consisting of termination and benefit costs for key management personnel in the same quarter last year, and decreases in business development costs, training costs, and insurance costs, partially offset by increases in share-based compensation, professional fees, and recruiting fees. Net Earnings Net earnings for the three months ended June 30, 2025 were $0.2 million, representing an increase of $3.0 million, from a net loss of $2.8 million for the three months ended June 30, 2024. The increase was due primarily to the increased gross margin, driven by higher revenues and positive contributions from the acquisitions of XRM Vision and eVerge, decreased selling, general and administrative expenses, and increased income tax recovery, partially offset by increased business acquisition, integration and reorganization costs, due primarily to the eVerge Acquisition, increased amortization of intangibles, increased foreign exchange loss, and increased net financial expenses for the three months ended June 30, 2025, compared to the three months ended June 30, 2024. On a per share basis, this translated into basic and diluted earnings per share of nil for the three months ended June 30, 2025, compared to a loss of $0.03 per share for the three months ended June 30, 2024. Adjusted Net Earnings Adjusted Net Earnings amounted to $6.5 million for the three months ended June 30, 2025, representing an increase of $1.6 million, or 31.8%, from $4.9 million for the three months ended June 30, 2024. As explained above, increased gross margin, driven by higher revenues and positive contributions from the acquisitions of XRM Vision and eVerge, decreased selling, general and administrative expenses, and increased income tax recovery were partially offset by increased foreign exchange loss and increased net financial expenses. This translated into Adjusted Net Earnings per Share of $0.07 for the three months ended June 30, 2025, compared to $0.05 for the three months ended June 30, 2024. Adjusted EBITDA Adjusted EBITDA amounted to $11.6 million for the three months ended June 30, 2025, representing an increase of $1.5 million, or 15.6%, from $10.1 million for the three months ended June 30, 2024. As explained above, the increase was due primarily to increased gross margin, driven by higher revenues and positive contributions from the acquisitions of XRM Vision and eVerge, and decreased selling, general and administrative expenses. Adjusted EBITDA Margin was 9.4% for the three months ended June 30, 2025, compared to 8.3% for the three months ended June 30, 2024. Bookings Bookings amounted to $118.1 million, which translated into a Book-to-Bill Ratio of 0.95 for the quarter, compared to $98.2 million, which translated into a Book-to-Bill Ratio of 0.81, for the same quarter last year. Bookings for the trailing twelve months amounted to $440.6 million as at June 30, 2025, which translated into a Book-to-Bill ratio of 0.92. If revenues from the two long-term contracts signed as part of an acquisition in the first quarter of fiscal year 2022 were excluded, the Book-to-Bill ratio would be 1.06, compared to 0.92 for the same quarter last year. For the trailing twelve months as at June 30, 2025, the Book-to-Bill ratio, excluding revenues from the two long-term contracts, would be 1.03. Liquidity and Capital Resources For the three months ended June 30, 2025, net cash used in operating activities was $4.2 million, representing a decrease of $20.9 million, from $16.7 million of cash generated for the three months ended June 30, 2024. The decrease in net cash from operating activities compared to the same quarter last year was mainly driven by unfavorable changes in non-cash working capital items. Unfavorable changes in non-cash working capital items of $12.9 million during the three months ended June 30, 2025 were due mainly to the timing of payments, collections, and invoicing and consisted primarily of a $9.1 million decrease in accounts payable and accrued liabilities, an $8.0 million increase in unbilled revenues, a $6.5 million decrease in deferred revenues, and a $1.2 million increase in tax credits receivable, partially offset by an $11.5 million decrease in accounts receivable and other receivables and a $0.3 million decrease in prepaids. For the three months ended June 30, 2024, favorable changes in non-cash working capital items of $9.4 million were due mainly to the timing of payments, collections, and invoicing and consisted primarily of a $15.1 million decrease in accounts receivable and other receivables and a $7.9 million decrease in tax credits receivable, partially offset by a $7.5 million increase in unbilled revenues, a $3.7 million decrease in accounts payable and accrued liabilities, a $1.5 million decrease in deferred revenues, and a $0.9 million increase in prepaids. As at June 30, 2025, drawings on the Credit Facility amounted to $96.1 million, after the impact of the eVerge acquisition during the quarter, and the availability of additional capital resources of Alithya amounted to $115.7 million, consisting of cash and availability under its credit facilities, including the accordion provision. Management believes that the Company is well positioned to sustain its operations while maintaining adequate levels of liquidity. eVerge Acquisition On May 31, 2025, Alithya acquired eVerge for a purchase price of US$23.5 million, payable in cash, including a potential earn-out of US$4.7 million. eVerge specializes in enterprise applications and transformation services with expertise in Salesforce Customer Relationship Management (CRM), and Oracle Human Capital Management (HCM) and Customer Experience (CX) and other complementary technologies. With a team of approximately 160 professionals, eVerge operates from locations across the U.S. and India. Forward-Looking Statements This press release contains statements that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian securities laws and the U.S. Private Securities Litigation Reform Act of 1995 and other applicable U.S. safe harbours (collectively "forward-looking statements"). Statements that do not exclusively relate to historical facts, as well as statements relating to management's expectations regarding the future growth, results of operations, performance and business prospects of Alithya, and other information related to Alithya's business strategy and future plans or which refer to the characterizations of future events or circumstances represent forward-looking statements. Such statements often contain the words "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "could," "would," "will," "may," "can," "continue," "potential," "should," "project," "target," and similar expressions and variations thereof, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include, among other things, information or statements about: (i) our ability to generate sufficient earnings to support our operations; (ii) our ability to take advantage of business opportunities and meet our goals set in our three-year strategic plan; (iii) our ability to maintain and develop our business, including by broadening the scope of our service offerings, by leveraging artificial intelligence ("AI"), our geographic presence and our smart shore capabilities, our expertise, and our integrated offerings, and by entering into new contracts and penetrating new markets; (iv) our strategy, future operations, and prospects, including our expectations regarding future revenue resulting from bookings and backlog and providing stakeholders with long-term growing return on investment; (v) our ability to service our debt and raise additional capital; (vi) our estimates regarding our financial performance, including our revenues, profitability, costs and expenses, gross margins, liquidity, capital resources, and capital expenditures; (vii) our ability to identify suitable acquisition targets and realize the expected synergies or cost savings relating to the integration of acquired entities, and (viii) our ability to balance, meet and exceed the needs of our stakeholders. Forward-looking statements are presented for the sole purpose of assisting investors and others in understanding Alithya's objectives, strategies and business outlook as well as its anticipated operating environment and may not be appropriate for other purposes. Although management believes the expectations reflected in Alithya's forward-looking statements were reasonable as at the date they were made, forward-looking statements are based on the opinions, assumptions and estimates of management and, as such, are subject to a variety of risks and uncertainties and other factors, many of which are beyond Alithya's control, and which could cause actual events or results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include but are not limited to those discussed in the section titled "Risks and Uncertainties" of Alithya's Management Discussion and Analysis ("MD&A") for the year ended March 31, 2025, as well as in Alithya's other materials made public, including documents filed with Canadian and U.S. securities regulatory authorities from time to time and which are available on SEDAR+ at and EDGAR at Additional risks and uncertainties not currently known to Alithya or that Alithya currently deems to be immaterial could also have a material adverse effect on its financial position, financial performance, cash flows, business or reputation. Forward-looking statements contained in this press release are qualified by these cautionary statements and are made only as of the date of this press release. Alithya expressly disclaims any obligation to update or alter any forward-looking statements, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by applicable law. Investors are cautioned not to place undue reliance on forward-looking statements since actual results may vary materially from them. Non-IFRS and Other Financial Measures This press release includes certain measures which have not been prepared in accordance with IFRS and other financial measures. Adjusted Net Earnings, Adjusted Net Earnings per Share, EBITDA, EBITDA Margin, Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS measures and Bookings, Book-to-Bill Ratio, Backlog, Gross Margin as a Percentage of Revenues and Selling, General and Administrative Expenses as a Percentage of Revenues are other financial measures used in this press release. These measures are provided as additional information to complement IFRS measures by providing further understanding of Alithya's results of operations from management's perspective. They do not have any standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. They should be considered as supplemental in nature and not as a substitute for the related financial information prepared in accordance with IFRS. They are used to provide investors with additional insight into Alithya's operating performance and thus highlight trends in Alithya's business that may not otherwise be apparent when relying solely on IFRS measures. Additional details for these non-IFRS and other financial measures can be found in section 5, "Non-IFRS and Other Financial Measures", of Alithya's MD&A for the quarter ended June 30, 2025, filed on SEDAR+ at and on EDGAR at which includes explanations of the composition and usefulness of these non-IFRS financial measures and non-IFRS ratios and is incorporated by reference in this press release. The following table reconciles net earnings to Adjusted Net Earnings: For the three months ended June 30, (in $ thousands) 2025 2024 $ $ Net earnings (loss) 185 (2,762) Business acquisition, integration and reorganization costs 2,047 783 Amortization of intangibles 4,955 4,644 Share-based compensation 2,372 1,685 Impairment of property and equipment and right-of-use assets and loss on lease termination 37 — Severance — 1,502 Income tax related to deferred tax asset recognized on purchase price allocation (1,948) — Effect of income tax related to above items (1,129) (908) Adjusted Net Earnings (a) 6,519 4,944 Basic and diluted earnings (loss) per share 0.00 (0.03) Adjusted Net Earnings per Share (a) 0.07 0.05 (a) Non-IFRS measure. See section 5 titled "Non-IFRS and Other Financial Measures" of Alithya's MD&A for the three months ended June 30, 2025, filed on SEDAR+ at and on EDGAR at The following table reconciles net earnings (loss) to EBITDA and Adjusted EBITDA: (a) Non-IFRS measure. See section 5 titled "Non-IFRS and Other Financial Measures" of Alithya's MD&A for the three months ended June 30, 2025, filed on SEDAR+ at and on EDGAR at First Quarter Conference Call Alithya will hold a conference call to discuss these results on August 13, 2025, at 9:00 a.m. Eastern Time. Interested parties can join the call by dialing 1-800-990-4777, or via webcast at A replay will be made available until August 20, 2025 (conference replay information: 1-888-660-6345, 86138#). About Alithya We are trusted advisors who leverage AI and the latest technologies in our strategic consulting and digital transformation services. We help solve business challenges that enable our clients to unlock new opportunities, modernize processes and gain efficiencies. We leverage a world-class team of passionate industry experts, AI-based IP solutions, the latest digital technologies, a solid understanding of mission critical business applications and a partner ecosystem to accelerate results. We've built a foundation of success that includes a specialized global delivery network to provide end-to-end solutions. We strive to make a difference. We are Alithya. Note to readers: Management's Discussion and Analysis and the interim consolidated financial statements and notes for the three months ended June 30, 2025 are available on SEDAR+ at on EDGAR at and on the Company's website at Shareholders may, upon request, receive a hard copy of these documents free of charge. SOURCE Alithya Group inc.
Toronto Star
17 hours ago
- Toronto Star
Acceleware Ltd. Announces Extension of Private Placement Financing
CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) — Acceleware® Ltd. ('Acceleware' or the 'Company') (TSX-V: AXE), a leading innovator of cutting-edge radio frequency ('RF') power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, is pleased to announce that the TSX Venture Exchange has agreed to extend the closing of additional tranches of its previously announced non-brokered private placement of units (the 'Units') that it previously announced on June 30, 2025 (the 'Private Placement'), to September 1, 2025. The first tranche of the Private Placement closed on July 31, 2025 for total gross proceeds of $791,334.20, as previously announced. Proceeds from the Private Placement will be used to fund a portion of the Company's RF XL 2.0 redeployment plan, to advance commercialization of new RF heating applications, including critical minerals applications and amine regeneration applications including carbon capture, and for general corporate purposes.
Globe and Mail
17 hours ago
- Globe and Mail
Oncocytoma Market Poised for Growth Through 2032, Fueled by AI Diagnostics and Minimally Invasive Surgery
The Oncocytoma market is experiencing notable growth, with the 7MM projected to achieve a decent CAGR, according to DelveInsight's latest analysis. This growth reflects advancements in molecular diagnostics and minimally invasive surgical technologies that are reshaping treatment paradigms for this rare renal and salivary gland tumor. DelveInsight's report, ' Oncocytoma - Market Insight, Epidemiology And Market Forecast - 2032 ', provides a comprehensive assessment of oncocytoma market dynamics, disease epidemiology, and treatment advancements across the 7MM. The report forecasts that the oncocytoma market size in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase notably over the coming years. This growth is primarily driven by the increased adoption of non-invasive treatment options and advancements in early detection technologies. The United States represents the largest share of the oncocytoma market. The EU4 countries and the United Kingdom collectively make up the second-largest market share. Download the oncocytoma market report to understand which factors are driving the oncocytoma therapeutic market @ Oncocytoma Market Trends. The epidemiological data presented in the report indicate key trends in incidence, demographics, and the oncocytoma patient pool. The data reveal a steadily expanding oncocytoma patient pool across the 7MM, with the median age at diagnosis for renal oncocytoma typically ranging from 62 to 68 years. Additionally, it has also been indicated that oncocytomas predominantly affect males across the studied regions. The report also explores the current and evolving Oncocytoma treatment landscape. As of now, there are no FDA-approved drugs specifically targeting oncocytoma. Instead, oncocytomas are typically managed through surgical excision (such as partial or radical nephrectomy) or minimally invasive techniques like cryoablation or radiofrequency ablation when necessary. While surgical intervention remains the cornerstone of current management, there is an accelerated innovation in diagnostic accuracy and the differentiation of these tumors from malignant renal counterparts. Recently, AI-driven diagnostic tools have been integrated into clinical practice, showing promising results in the diagnosis and preoperative planning for oncocytoma. One study revealed that an AI system achieved over 90% accuracy in distinguishing clear cell renal cell carcinoma (RCC) from oncocytoma using MRI scans. Additionally, a comparative analysis indicated that the AI model outperformed radiologists in distinguishing benign tumors, such as oncocytoma and angiomyolipoma, from RCC subtypes. This highlights the potential of AI to reduce diagnostic ambiguity within the oncocytoma treatment landscape. Discover evolving trends in the oncocytoma treatment landscape @ Oncocytoma Therapeutics Market. Looking ahead, the oncocytoma market is set for significant growth, driven by advancements in diagnostic technologies and surgical techniques. Despite challenges posed by the benign nature of these tumors, which can lead to misdiagnosis and potential overtreatment, the field is witnessing a paradigm shift. The integration of artificial intelligence in imaging and the development of molecular diagnostic tools are enhancing the accuracy of preoperative diagnosis, reshaping patient management strategies As research continues to uncover the molecular intricacies of oncocytomas, the market is expected to expand, offering more personalized treatment options and improved long-term monitoring techniques to address the unmet needs in this landscape. Unlock which oncocytoma drug is expected to capture the largest market share in 7MM by 2032. Visit the Oncocytoma Market Insights. Table of Contents 1. Key Insights 2. Executive Summary of Oncocytoma 3. Oncocytoma Competitive Intelligence Analysis 4. Oncocytoma: Market Overview at a Glance 5. Oncocytoma: Disease Background and Overview 6. Oncocytoma Patient Journey 7. Oncocytoma Epidemiology and Patient Population 8. Oncocytoma Treatment Algorithm, Current Treatment, and Medical Practices 9. Oncocytoma Unmet Needs 10. Key Endpoints of Oncocytoma Treatment 11. Oncocytoma Marketed Products 12. Oncocytoma Emerging Therapies 13. Oncocytoma: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Oncocytoma Access and Reimbursement Overview 17. KOL Views 18. Oncocytoma Market Drivers 19. Oncocytoma Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Oncocytoma Pipeline Insight Oncocytoma Pipeline Insight provides comprehensive insights about the oncocytoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the oncocytoma companies. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
